Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease through monitoring and therapeutic intervention technologies. The company's flagship product is the ASSURE Wearable Cardioverter Defibrillator (WCD), a non-invasive device prescribed to at-risk patients to detect and treat life-threatening ventricular arrhythmias. The ASSURE WCD received FDA Premarket Approval in 2021 and is positioned as a modern alternative to ZOLL's LifeVest, offering a significantly lower false-alarm rate. Headquartered in Kirkland, Washington, Kestra was founded in 2014 by industry veterans from the external (AED) and internal (ICD) defibrillation industries and originated as a portfolio company of Bain Capital Life Sciences. The company listed on the Nasdaq Global Select Market under the ticker KMTS in March 2025.
Kestra Medical Technologies is publicly traded
IPO'd on March 6, 2025
This company is no longer available on our private secondary market. Shares can be traded publicly under KMTS.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2014
Employees
400–450
Total Funding
$536M
3 rounds
Total raised $536M across 3 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
IPO
Date
March 6, 2025
Amount
$202M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| March 6, 2025 | IPO | $202M | — | IPO underwriters |
| July 24, 2024 | Series B / Late-stage growth | $196M | — | Andera Partners, Ally Bridge Group |
| January 1, 2014 | Series A | Not disclosed | — | Bain Capital Private Equity / Bain Capital Life Sciences |
Brian Webster
Founder, President & Chief Executive Officer
Vaseem Mahboob
Chief Financial Officer
Timothy Moran
Chief Business Officer
Traci Umberger
General Counsel & Chief Administrative Officer
Competitor list is illustrative and may be incomplete, stale, or erroneous.
ZOLL Medical (LifeVest)
Subsidiary of Asahi Kasei; maker of the LifeVest WCD, the long-incumbent wearable cardioverter defibrillator that has dominated the market for over two decades and is the primary competitor to Kestra's ASSURE WCD.
Element Science
Privately-held competitor developing the Jewel Patch WCD, a patch-based wearable cardioverter defibrillator that received FDA approval in May 2025 and offers an alternative form factor versus vest-based WCDs.
Medtronic
Global medtech leader in implantable cardioverter defibrillators (ICDs) and cardiac monitoring; competes adjacent to the WCD category by providing implantable alternatives for at-risk arrhythmia patients.
Boston Scientific
Major cardiovascular device manufacturer producing implantable defibrillators including the subcutaneous S-ICD; competes with WCDs as the longer-term therapeutic option for many at-risk patients.
Yes, Kestra Medical Technologies is publicly traded under the ticker symbol KMTS on the Nasdaq Global Select Market. The company went public in March 6, 2025.
Kestra Medical Technologies trades under the ticker symbol KMTS on the Nasdaq Global Select Market. It began trading in March 6, 2025.
Kestra Medical Technologies (KMTS on the Nasdaq Global Select Market) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker KMTS to place an order.
Kestra Medical Technologies went public in March 6, 2025 via ipo. Kestra Medical Technologies completed its initial public offering on the Nasdaq Global Select Market on March 6, 2025, trading under the ticker symbol KMTS. The upsized IPO priced 11,882,352 common shares at $17.00 per share (above the initial $14-$16 range), with gross proceeds of approximately $202 million. After the underwriters' over-allotment was fully exercised on March 14, 2025, total shares sold reached 13,664,704 for gross proceeds of approximately $232 million. BofA Securities, Goldman Sachs and Piper Sandler served as lead bookrunners. Shares opened at $22.95, more than 30% above the IPO price. In December 2025, Kestra announced a follow-on primary public offering of 5,500,000 common shares.
Kestra Medical Technologies raised $536M across 3 disclosed funding rounds prior to its public listing.
Kestra Medical Technologies was founded by Brian Webster in 2014.
Kestra Medical Technologies is headquartered in Kirkland, WA.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.